Is Attending BIO CEO A Waste Of Your Time?
Sometimes it is worthwhile to stop and consider the value of your time, not from a financial perspective, but rather how much you’ve used and how much you have left. If you did, you might be much more discriminating in where you would choose to spend it. Consider this: the average U.S. male’s life expectancy is 76. This means that in less than 14,600 hours my time fuel tank will be exactly one-third full, or depending on your...
Continue Reading..
What Does It Take To Be The World's Top Performing CEO?
In November 2015, the Harvard Business Review (HBR) announced the top 100 CEOs in the world. Though the list included household names like Starbucks (12), Nike (21), and Amazon (87), what is even more interesting than the fact that Novo Nordisk’s Lars Rebien Sørensen was ranked number one, was the healthcare industry as a whole had 13 CEOs in the top 100 — tying it for first with financial service (see Table 1). But if you dig...
Continue Reading..
What Is The Solution To “High-Price” Drug Sticker Shock?
Last November, lawmakers and the Obama administration began ratcheting up efforts targeted at pharmaceutical company’s “high-priced drugs.” Some view this as a sign that legislators are trying to bridge the political divide to tackle a key driver of rising healthcare costs. But are high-priced drugs and biopharmaceutical companies the most important driver to target?
Continue Reading..
What Surprised Me — And Didn't — At J.P. Morgan 2016
Unfortunately, a minor mechanical issue involving one of my flights caused me to arrive a day late for the 34th Annual J.P. Morgan Healthcare Conference (JPM) in San Francisco (January 11-14). While missing Monday at one of biopharma’s biggest annual events translates to a huge lost opportunity, when it comes to JPM, one day does not a conference make.
Continue Reading..
What Is Going To Be The Next Big Thing For Biopharma In 2016?
There are plenty of industry insights available, such as Life Science Leader’s comprehensive December 2015 Outlook issue for 2016 or our four-part trendsetter series. And while these provide a wealth of insight, I felt compelled to put together one last blog to prevent you from being blindsided by the “Next Big Thing” in biopharma in 2016.
Continue Reading..
What Guides Your Company?
If you have ever seen an employee of Johnson and Johnson speak, you probably recall that at some point during their presentation they probably made reference to “Our Credo” — a J&J document that describes the values used to guide employee decision making. “Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.” Written in 1943 by Robert Wood Johnson, former chairman and...
Continue Reading..
The Folly Of Burying Great Insight
Last week I posted “Why The Wall Street Journal’s U.S. Drug Price Comparison Misses The Mark,” a criticism of health and science deputy bureau chief Jeanne Whalen’s Dec. 1, 2015 article titled, “U.S. Drug Prices Dwarf Other Nations.” What bothered me about this article was that I felt it skewed the facts, sensationalized the issue, and seemed intent on stirring up controversy.
Continue Reading..
FDA/CMS Summit Demonstrates Need For Innovative Hiring Solutions
When Janet Woodcock, M.D., kicked of this year’s FDA/CMS Summit for biopharmaceutical executives, the FDA’s director for the Center for Drug Evaluation & Research (CDER) did so by recapping what was achieved in 2015, as well as sharing her lengthy list of priorities for the coming year. According to Woodcock, the challenge to successful implementation of various priorities is analogous to keeping an airplane flying while at the...
Continue Reading..
Why The Wall Street Journal's U.S. Drug Price Comparison Misses The Mark
In the December 1, 2015 edition of the Wall Street Journal there is an article titled, “U.S. Drug Prices Dwarf Other Nations.” The author, health and science deputy bureau chief Jeanne Whalen, begins by pointing out that Norway, an oil producer with one of the richest economies in the world, is an expensive place to live. To support her claim she highlights Norway’s cost of a Big Mac ($5.65) and a gallon of gasoline ($6). But...
Continue Reading..
There's More To January Than Just the JPM Conference
One of the biggest biopharmaceutical industry events, the 34th Annual JP Morgan Healthcare Conference, is right around the corner, January 11-14. And while the event is famous for overrunning San Francisco with neckties, as well as blowing up Twitter with its hashtag #JPM2016, there are a number of other worthwhile events also taking place.
Continue Reading..
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL
This website uses cookies to ensure you get the best experience on our website. Learn more